[Value of prostaglandin E1 in cardiac malformations in the newborn infant]
- PMID: 6504667
[Value of prostaglandin E1 in cardiac malformations in the newborn infant]
Abstract
Prostaglandin E1 (PGE1) was administered to increase ductus patency in 26 neonates who present a cyanotic heart disease with right ventricular obstruction (1st group, 13 cases) or congestive heart failure with left ventricular outflow obstruction (2nd group, 13 cases). Clinical improvement occurred in all but the oldest infant in the first group. The efficacy of PGE1 is inconstant in the second group, but medical status was very poor before treatment. We could usually reduce the dose of PGE1 but in no case we could stop the drug before surgery. Surgery could be delayed several hours or days to get an hemodynamic and biologic satisfactory condition and even a few weeks until the infants and their pulmonary arteries had grown (1st group). Side effects are common but relatively minor.
Similar articles
-
Use of prostaglandin E1 for maintaining the patency of the ductus arteriosus.Adv Prostaglandin Thromboxane Res. 1978;4:355-62. Adv Prostaglandin Thromboxane Res. 1978. PMID: 347914 Clinical Trial.
-
Nursing care of the neonate receiving prostaglandin E1 therapy.Neonatal Netw. 1993 Jun;12(4):17-22. Neonatal Netw. 1993. PMID: 8510622
-
[Effects of prostaglandin in heart abnormalities with needed patency of the arterial canal (clinical and histological study)].Arch Fr Pediatr. 1978 Aug-Sep;35(7):717-25. Arch Fr Pediatr. 1978. PMID: 736728 French.
-
Evaluation of alprostadil (prostaglandin E1) in the management of congenital heart disease in infancy.Pharmacotherapy. 1982 May-Jun;2(3):148-55. doi: 10.1002/j.1875-9114.1982.tb04522.x. Pharmacotherapy. 1982. PMID: 6763200 Review.
-
Cardiovascular therapy in the newborn.Clin Invest Med. 1985;8(4):360-7. Clin Invest Med. 1985. PMID: 3907921 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical